Possible sale on the horizon for MedTech business

A potential sale is on the cards for Leeds-headquartered regenerative medical devices company, Tissue Regenix Group.

The business has today confirmed it is conducting a review of its strategic options “that may include soliciting offers for the company.”

Its update adds: “As part of this, the company has contacted a limited number of potential counterparties to assess whether such parties could put forward a proposal that would deliver greater value to Tissue Regenix’s shareholders than pursuing a standalone independent strategy.

“The company has not received any indicative non-binding proposals to date.

“There can be no certainty that any offer will be made as a result of contact with these potential counterparties, nor as to the terms on which any such offer might be made. Shareholders are advised to take no action at this time.

“A further announcement will be made in due course.”